Literature DB >> 15234242

Apoptotic markers in cancer.

S Holdenrieder1, P Stieber.   

Abstract

In cancer, apoptotic processes occur both spontaneously and induced by antitumor therapies. Qualitative and quantitative changes in cancer cell death along with proliferative alterations are essential determinants in the pathogenesis and progression of malignant disease and its responsiveness to therapy. Besides detecting apoptosis by invasive means in tumor tissue, apoptotic products can be quantified in the circulation. Although circulating apoptotic products usually lack organ and tumor specificity, they contribute in the assessment of disease extent or aggressiveness. The ease of drawing blood facilitates the serial measurement of circulating apoptotic markers to monitor antitumor treatment and predict early response to therapy. This review describes the features of apoptotic and necrotic cell death along with the role the balance between the rates of cell death and cell proliferation plays in the progression of malignancy. The intracellular pathways mediating apoptosis are next summarized. The focus then shifts to the apoptotic markers found in the circulation and their diagnostic, prognostic, predictive, and management utility in cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234242     DOI: 10.1016/j.clinbiochem.2004.05.003

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  25 in total

Review 1.  Apoptosis by dietary agents for prevention and treatment of cancer.

Authors:  Naghma Khan; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Biochem Pharmacol       Date:  2008-07-22       Impact factor: 5.858

2.  The plasma DNA concentration as a potential breast cancer screening marker.

Authors:  Orathai Tangvarasittichai; Watchiravut Jaiwang; Surapon Tangvarasittichai
Journal:  Indian J Clin Biochem       Date:  2013-11-22

3.  Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.

Authors:  Michael Frezza; Huanjie Yang; Q Ping Dou
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

4.  Antiproliferative activity of vitexin-2-O-xyloside and avenanthramides on CaCo-2 and HepG2 cancer cells occurs through apoptosis induction and reduction of pro-survival mechanisms.

Authors:  Emanuele Salvatore Scarpa; Elena Antonini; Francesco Palma; Michele Mari; Paolino Ninfali
Journal:  Eur J Nutr       Date:  2017-03-10       Impact factor: 5.614

5.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

6.  A novel role of serum cytochrome c as a tumor marker in patients with operable cancer.

Authors:  Akemi Osaka; Hiroo Hasegawa; Yasuaki Yamada; Katsunori Yanagihara; Tomayoshi Hayashi; Mariko Mine; Muneo Aoyama; Takashi Sawada; Shimeru Kamihira
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-30       Impact factor: 4.553

7.  Bax protein may influence the invasion of colorectal cancer.

Authors:  Anna Pryczynicz; Mariusz Gryko; Katarzyna Niewiarowska; Dariusz Cepowicz; Marek Ustymowicz; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

8.  Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.

Authors:  Jian-Mei Hou; Alastair Greystoke; Lee Lancashire; Jeff Cummings; Tim Ward; Ruth Board; Eitan Amir; Sarah Hughes; Matthew Krebs; Andrew Hughes; Malcolm Ranson; Paul Lorigan; Caroline Dive; Fiona H Blackhall
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

9.  Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-11

10.  Circulating cell death products predict clinical outcome of colorectal cancer patients.

Authors:  Pim J Koelink; Cornelis Bhw Lamers; Daan W Hommes; Hein W Verspaget
Journal:  BMC Cancer       Date:  2009-03-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.